A FUNDED CLINICAL TRIAL TO EVALUATE A NOVEL IMMUNOTHERAPY IN DOGS WITH MELANOMA AND MAST CELL TUMORS

Study Objective: 

This trial is designed to evaluate the safety and preliminary anti-cancer activity of a novel, monoclonal antibody in dogs with measurable cancer.  An estimated 20 client-owned dogs with Melanoma or Mast Cell Tumors will be enrolled.  The antibody is administered IV by the study staff every 14 days for up to 10 treatments.  No placebo is used in this trial. Visits will be required every 2 weeks for a total trial period of 140 days.

Eligibility Requirements: 

Mast Cell Tumors

  • At least one measurable skin tumor +/- metastatic lymph node(s) > 2 cm
  • Prior therapy accepted with washout times to be discussed at the participating site

Melanoma

  • At least one measurable malignant tumor in the oral cavity, digit, skin +/- metastatic lymph node > 2 cm
  • Prior therapy accepted with washout times to be discussed with site
Exclusion Criteria: 

Mast Cell Tumors

  • No intraabdominal metastasis

Melanoma

  • No pulmonary metastasis
Compensation: 
The trial is fully funded for the full trial duration (140 days), including the antibody and trial-related procedures.
Location of Trial: 
Norwalk, CT

Click here for more information